Daily Endocrinology Research Analysis
Analyzed 83 papers and selected 3 impactful papers.
Summary
Analyzed 83 papers and selected 3 impactful articles.
Selected Articles
1. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
Across 262 RCTs, tirzepatide, CagriSema, and semaglutide produced the largest one-year weight loss but with higher GI adverse events and discontinuations. Subcutaneous semaglutide uniquely reduced all-cause mortality and myocardial infarction; both semaglutide and tirzepatide reduced heart failure risk, while most agents did not meaningfully improve quality of life.
Impact: This synthesis provides the most current, comparative, and methodologically rigorous map of efficacy–safety trade-offs across modern anti-obesity agents, directly informing shared decision-making and policy.
Clinical Implications: Select agents based on individualized benefit–risk: prioritize semaglutide where cardiovascular benefit is desired; counsel about GI adverse events; set realistic expectations for quality-of-life change; integrate lifestyle and resistance exercise to preserve lean mass.
Key Findings
- At one year, tirzepatide (~−14.9%), CagriSema (~−14.8%), and semaglutide (oral ~−10.9%; subcutaneous ~−9.8%) led weight loss versus lifestyle alone.
- GI adverse events and discontinuations were more frequent with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide.
- Subcutaneous semaglutide reduced all-cause mortality (RR 0.81) and myocardial infarction (RR 0.72); semaglutide and tirzepatide reduced heart failure risk.
- Quality-of-life improvements generally did not exceed minimally important differences.
Methodological Strengths
- Large-scale network meta-analysis of 262 RCTs with GRADE and ROB2 assessments
- Use of both frequentist random-effects and Bayesian dose–response models to test robustness
Limitations
- Substantial heterogeneity and reliance on indirect comparisons for several agents
- Quality-of-life outcomes showed limited improvements despite weight loss, and emerging agents had low-certainty evidence
Future Directions: Head-to-head RCTs for leading agents, standardized adverse event and QoL reporting, long-term cardiometabolic outcomes, and strategies to preserve lean mass during pharmacotherapy.
OBJECTIVE: To provide an up-to-date evidence summary about the comparative benefits and harms of drugs for adults with overweight or obesity to inform decision making for policymakers, payers, clinicians, and patients. DESIGN: Systematic review and network meta-analysis of 24 outcomes using frequentist random effects models and bayesian dose-response models, the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, and the Cochrane Risk of Bias 2 tool. DATA SOURCES: Medline, Embase, and Cochrane Library, searched up to 12 November 2025. STUDY SELECTION: Randomised controlled trials of 12 weeks' duration or longer comparing one or more drugs with lifestyle modification, placebo, or another drug. RESULTS: This network meta-analysis comprised 262 trials (99 791 participants) evaluating 19 drugs with follow-up from 12 to 172 weeks. Compared with lifestyle modification alone, at one year, moderate to high certainty evidence shows substantial weight loss with tirzepatide (mean difference -14.9%, 95% confidence interval -16.0% to -13.9%), cagrilintide-semaglutide (CagriSema, -14.8%, -16.9% to -12.7%), oral semaglutide (-10.9%, -12.7% to -9.1%), orforglipron (-9.9%, -12.4% to -7.5%), subcutaneous semaglutide (-9.8%, -10.6% to -9.1%), and phentermine-topiramate (-8.1%, -9.7% to -6.5%). Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce similar or greater reductions (13.1-14.6%; very low to low certainty). Moderate to high certainty evidence supports discontinuation because of adverse events to be highest with orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, CagriSema, and oral semaglutide (risk ratios from 1.9 to 4.2); gastrointestinal events were most increased with naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide (risk ratios from 3.1 to 4.2). Fatigue risk increased, particularly with naltrexone-bupropion (risk ratio 8.9; absolute increase 331 per 1000 people over one year), orforglipron
2. Markers of compromised gut epithelial barrier integrity increase during the menopause transition.
In a longitudinal cohort of 964 women, serum FABP2 and sCD14 rose across the menopause transition, beginning ~2.5 years pre-FMP and peaking ~6–6.5 years post-FMP, independent of race/ethnicity, BMI, or age at FMP. Findings translate animal evidence to humans, implicating gut barrier compromise as an inflammatory pathway in menopause.
Impact: Provides human longitudinal evidence linking menopause transition to compromised gut barrier markers, bridging mechanistic gaps and suggesting new inflammatory targets.
Clinical Implications: Encourages consideration of gut barrier–directed strategies (nutrition, microbiome-targeted interventions) during midlife to mitigate inflammation, while emphasizing the need for interventional trials.
Key Findings
- FABP2 began increasing ~2.5 years before FMP; sCD14 followed ~6 months later, peaking 6–6.5 years after FMP.
- Annual increases during the ~9-year interval were 2.6% for FABP2 and 0.8% for sCD14 in models adjusted for age at FMP, race/ethnicity, and BMI.
- Change rates did not differ by race/ethnicity, BMI, or age at FMP, indicating a generalizable pattern.
Methodological Strengths
- Prospective, repeated-measures design with piece-wise linear mixed-effects modeling anchored to FMP
- Adjustment for key confounders (age at FMP, race/ethnicity, BMI) and long temporal window across MT
Limitations
- Serum markers infer gut barrier compromise and microbial translocation but lack direct permeability measures
- Observational design precludes causal inference and does not test interventions
Future Directions: Interventional trials targeting gut barrier integrity during menopause (dietary fibers, probiotics, postbiotics) and mechanistic studies linking marker changes to clinical inflammatory outcomes.
BACKGROUND: In female murine models, one source of inflammation is a menopause-related increase in gut permeability. We examined whether the menopause transition (MT) in women is associated with an increase in markers of gut epithelial dysfunction and gut microbial product translocation, signals of compromised gut epithelial barrier integrity. METHODS: In 964 women, we measured markers of gut epithelial dysfunction (fatty acid binding protein 2, FABP2) and gut microbial antigen translocation (soluble CD14, sCD14) using sera collected before, during and after the MT. Multivariable mixed effects regressions fit piece-wise linear models to repeated FABP2 or sCD14 measures relative to time from final menstrual period (FMP). Covariates were age at FMP, race/ethnicity, and BMI. RESULTS: FABP2 and sCD14 did not change significantly until 2.5 years pre-FMP. At that point, FABP2 began rising; sCD14 began increasing 6 months later. FABP2 and sCD14 peaked 6 and 6.5 years post-FMP, respectively; subsequent levels remained stable. During the ~9-year interval of MT-related gain in gut barrier compromise markers, annual FABP2 and sCD14 increases were 2.6% (95% CI: 1.7 to 3.4%) and 0.8% (95% CI: 0.6 to 1.1%), respectively, among white women with sample-average BMI and age at FMP. FABP2 and sCD14 change rates did not differ significantly by race/ethnicity, BMI, or age at FMP. CONCLUSIONS: The MT is associated with a rise in markers of compromised gut barrier integrity, suggesting that this pathway of inflammation, previously described in animal models, occurs in humans. FUNDING: NIH U01NR004061, U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG012553, U01AG012554, U01AG012495, 5R01AR081794.
3. Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes.
In DCCT participants, nearly all DKA events occurred when prior-year C-peptide was ≤0.2 nmol/L; detectable C-peptide >0.2 nmol/L conferred a ~93% relative risk reduction for DKA. Findings support beta-cell–preserving therapies to mitigate long-term DKA risk.
Impact: Quantifies the protective association of residual endogenous insulin with recurrent DKA using robust recurrent-event modeling, guiding risk stratification and therapeutic priorities in type 1 diabetes.
Clinical Implications: Consider residual C-peptide status in DKA risk assessment; prioritize interventions that preserve beta-cell function (e.g., immunotherapy, hybrid closed-loop with careful surveillance) and tailor education and sick-day rules for individuals with low/absent C-peptide.
Key Findings
- 179/180 (99.44%) DKA events occurred when prior-year C-peptide was ≤0.2 nmol/L; only one event occurred with >0.2 nmol/L.
- Detectable stimulated C-peptide >0.2 nmol/L was associated with an adjusted DKA hazard ratio of 0.07 (95% CI 0.01–0.48).
- Results were consistent across crude and adjusted Andersen–Gill recurrent-event models over ~6.5 years.
Methodological Strengths
- Use of DCCT dataset with standardized annual stimulated C-peptide measurements
- Time-dependent Andersen–Gill models accounting for recurrent events and covariates
Limitations
- Secondary analysis; C-peptide threshold and measurement frequency may not reflect routine clinical practice
- Causality cannot be inferred; generalizability beyond DCCT-era management requires caution
Future Directions: Prospective validation in contemporary cohorts, integration of continuous C-peptide assessments, and trials of beta-cell–preserving therapies with DKA as a pre-specified outcome.
OBJECTIVE: To investigate whether detectable C-peptide levels in type 1 diabetes is associated with a lower risk of diabetic ketoacidosis (DKA). RESEARCH DESIGN AND METHODS: We analyzed the Diabetes Control and Complications Trial publicly available data repository for the association between detectable stimulated C-peptide (>0.2 nmol/mL, measured annually) and DKA incidence over an average 6.5-year follow-up. We used crude and adjusted Andersen-Gill models for recurrent DKA events with time-dependent covariates. RESULTS: Of the 1,441 participants (53% male, median age 27 years), 129 (9%) experienced 180 DKA events. Of these events, 179 (99.44%) occurred after C-peptide was ≤0.2 nmol/L in the prior year and only 1 event occurred with C-peptide >0.2 nmol/L. C-peptide >0.2 nmol/L was associated with a DKA hazard ratio of 0.07 (95% CI 0.01-0.48; P = 0.007), consistent across adjusted models. CONCLUSIONS: Endogenous insulin production was significantly associated with lower DKA risk, suggesting that treatments preserving insulin production could decrease long-term DKA risk.